Fresenius Kabi this week announced its Ivenix infusion system was awarded an Innovative Technology contract from Vizient.

Vizient members include more than half of all acute care hospitals in the U.S., and the Innovative Technology contracts are recommended after review and interaction with products submitted through the organization’s program. The contract sets terms for hospitals to evaluate and purchase the Ivenix system.

“We are thrilled to be awarded an Innovative Technology contract from Vizient for the Ivenix Infusion System,” Fresenius Kabi Medtech President Christian Hauer said in a news release. “The Vizient Innovative Technology process is a rigorous, clinician-led review, and we are proud that they concluded that the Ivenix Infusion System has the potential to advance clinical efficiency and improve patient outcomes. This validates the customer experience and feedback we have received to date. We are honored to be awarded this Vizient contract and welcome the opportunity to offer Vizient members, clinicians and patients this exciting infusion technology.”

Fresenius Kabi’s Ivenix infusion system has a large-volume pump, a portfolio of administration sets and a suite of infusion management tools that work together to inform care, advance clinical efficiency and reduce costs. The company designed the infusion platform to integrate with hospital electronic medical records and other information systems.

“A product receives this type of contract when it demonstrates a unique quality that differentiates it from other products on the market,” said Kelly Flaharty, senior director of contract services for Vizient. “Our member council determined that Fresenius Kabi’s Ivenix Infusion System met this standard and recognizes its potential to improve quality outcomes.”